In ovarian cancer, which is a disease known to present in advanced stages, the impact of TGF-β as a promoter of tumor progression appears to dominate, making it an intriguing biomarker of ovarian cancer from both a prognostic and therapeutic standpoint. Here, TGFB1 is linked to neoplasm.